News!
$Liquidia(LQDA.US$ The FDA Informed Liquidia That It Is Adding Pulmonary Hypertension Associated With Interstitial Lung Disease Indication As An Amendment To Yutrepia Application, Hence It Will Not Be Able To Meet The Prescription Drug User Fee Act Goal Date Of January 24. , and their review remains ongoing. The FDA did not request any additional clinical data to support the NDA and did not issue a new PDUFA goal date.
Moomoo 24/7· 2 mins ago![]()
Moomoo 24/7· 2 mins ago
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
JESSE JAMES8832 : glad i didnt buy in here
Trytosaveabit OP JESSE JAMES8832 : Good morning! Yeah you and me both! Amazing isnt how the FDA can just like that extend the time needed just because the company wants to add another treatment to which the medication can treat? GL today![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")